Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for grade 2-3 radiation-induced lung injury
ChiCTR2200064594Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pirfenidone in radiation-induced lung injury (RILI) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Change in DLco% from baseline. Started Nov 2021; status: completed.
02
Drugs
pirfenidone
03
Conditions
radiation-induced lung injury (RILI)
Beyond the preview
Go deeper on ChiCTR2200064594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064594.